At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1 enrolled
Drug / intervention
Ivacaftor/Atalurendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Investigate the Role of Ivacaftor for the Treatment of Cystic Fibrosis in Combination With Ataluren (PTC124) in Cystic Fibrosis Patients Using Ataluren for Nonsense Mutations
In Brief
A Phase 4 clinical trial evaluating Ivacaftor/Ataluren for Cystic Fibrosis. Completed, enrolled 1 participant across 1 site.
Detailed Summary
The purpose of this study is to explore the combination of Ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
Primary CompletionJul 2017
First PostedAug 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedAug 22, 2017
Enrollment StartMar 17, 2017
Primary CompletionJul 10, 2017
Study CompletionFeb 16, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.9 years ago
Interventions
Ivacaftor/Atalurendrug
Both drugs were given in combination for 48 week study period